Cidofovir: to use or not to use?

@article{Soma2008CidofovirTU,
  title={Cidofovir: to use or not to use?},
  author={M. Soma and D. Albert},
  journal={Current Opinion in Otolaryngology \& Head and Neck Surgery},
  year={2008},
  volume={16},
  pages={86–90}
}
  • M. Soma, D. Albert
  • Published 2008
  • Medicine
  • Current Opinion in Otolaryngology & Head and Neck Surgery
Purpose of reviewCidofovir is an antiviral agent that has been used increasingly in the last decade as an adjuvant therapy for recurrent respiratory papillomatosis. It has been used in patients with moderate to severe recurrent respiratory papillomatosis requiring frequent surgical intervention or if there is evidence of distal spread. Intralesional administration after surgical debulking delivers the medication directly to the site of disease and is thought to have fewer systemic side effects… Expand
Pharmacotherapy of recurrent respiratory papillomatosis: an expert opinion
TLDR
The evidence supporting each of these adjuncts varies with a majority having only case reports or cases-series to support their use, but there is hope on the horizon with regard to the HPV vaccine and its potential to prevent future transmission of this disease. Expand
Effectiveness of cidofovir intralesional treatment in recurrent respiratory papillomatosis
TLDR
Intralesional cidofovir injection has been shown to be an effective and safe therapy for laryngeal papillomatosis and should be considered in those patients who experienced disease relapse. Expand
Treatment of recurrent respiratory papillomatosis lung involvement by cidofovir infusion
TLDR
The reported case is one of rare pulmonary involvement in RRP and shows the effectiveness of intravenous cidofovir alone on symptoms, high-resolution computed tomography abnormalities, and pulmonary function tests. Expand
The impact of cidofovir treatment on viral loads in adult recurrent respiratory papillomatosis
TLDR
It is concluded that viral load of HPV can be monitored using the technique described here and cidofovir in combination with surgical debulking reduces the viral load in patients with RRP. Expand
Degrees of dysplasia and the use of cidofovir in patients with recurrent respiratory papillomatosis
TLDR
This study aims to explore the association between increasing degree of papilloma dysplasia and the use of cidofovir in the context of the natural progression of Dysplasia in RRP. Expand
Adult Recurrent Respirator Papillomatosis
TLDR
A new adjuvant treatment based on immunogenetic mechanisms against human laryngeal papilloma virus, with expectations of reducing disease aggressiveness and the number of operations, avoids the risks of surgery. Expand
Operative management of juvenile-onset recurrent respiratory papillomatosis
TLDR
The quadrivalent HPV vaccine (Gardisil; Merck, NJ) is promising to reduce the HPV infection rate in young women, with the hope that by eliminating this reservoir of disease, the incidence of HPV-related illnesses, juvenile-onset including recurrent respiratory papillomatosis, will dramatically drop. Expand
Human papilloma virus vaccination in patients with an aggressive course of recurrent respiratory papillomatosis
TLDR
Vaccination with the quadrivalent HPV vaccine can favorably influence the course of RRP in patients with the rapid growth of the papillomas and significantly prolongs the intervals between the surgical procedures and reduces the number of procedures needed in the majority of patients. Expand
An overview of early investigational drugs for the treatment of human papilloma virus infection and associated dysplasia
TLDR
Combining a suitable topically-applied and low-cost antiviral treatment with self-sampled HPV testing could revolutionise the management of this disease in the developing world which lack both the infrastructure and resources to establish national cytology screening programs. Expand
Recurrent respiratory papillomatosis of the airway: The experience of an endoscopic unit.
TLDR
Endoscopic treatment is important for the removal of the papillomas that are not accessible via laryngoscopy and for resistant moderate/severe cases of RPP because it allows intralesional administration of adjuvant therapy like cidofovir. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 38 REFERENCES
Antiviral agents for the treatment of recurrent respiratory papillomatosis: A systematic review of the English-language literature
  • N. Chadha, A. James
  • Medicine
  • Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • 2007
TLDR
Insufficient evidence from controlled trials exists for reliable conclusions, but several series indicate intralesional cidofovir may have some efficacy, and a well-designed placebo-controlled, double-blinded, randomized controlled trial is needed. Expand
Case of Progressive Dysplasia Concomitant with Intralesional Cidofovir Administration for Recurrent Respiratory Papillomatosis
TLDR
A 28-year-old woman with recurrent respiratory papillomatosis who was treated with intralesional cidofovir at the time of surgery over the span of 27 months demonstrated benign disease with progression to severe dysplasia during the treatment time. Expand
Intralesional cidofovir for recurrent respiratory papillomatosis in children.
TLDR
Intralesional injection of cidofovir seems to be of benefit in the treatment of severe respiratory papillomatosis in pediatric patients, and larger prospective studies with longer follow-up will be required before cid ofovir can be considered an accepted means of managing this difficult disease. Expand
Adjuvant antiviral therapy for recurrent respiratory papillomatosis.
TLDR
There is insufficient evidence to support the efficacy of antiviral agents as adjuvant therapy in the management of recurrent respiratory papillomatosis in children or adults. Expand
Delivery of Cidofovir to Respiratory Papillomas of the Distal Trachea
TLDR
Recurrent respiratory papillomatosis is the most common benign neoplasm of the larynx in children and progression to lower airway and pulmonary involvement may ultimately lead to death; however, the clinical course is unpredictable and treatment of lesions in this area is likewise challenging. Expand
Successful treatment of juvenile laryngeal papillomatosis-related multicystic lung disease with cidofovir: case report and review of the literature.
TLDR
It is reported the first case where IV cidofovir was used successfully to treat a rare but lethal multicystic lung disease complicating JLP, and demonstrates that cid ofovir may be usedsuccessfully to treat JLP-related lung disease. Expand
A Staging System for Assessing Severity of Disease and Response to Therapy in Recurrent Respiratory Papillomatosis
TLDR
Recurrent respiratory papillomatosis is an orphan disease with an incidence in the United States estimated at between 1500 and 2500 new cases per year, and is considered the most common benign neoplasm of the larynx. Expand
Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)‐1‐(3‐hydroxy‐2‐phosphonylmethoxypropyl)cytosine]
TLDR
Intratumoral injections of cidofovir for the treatment of severe laryngeal papillomatosis is a powerful new therapeutic approach for this disease. Expand
Intralesional cidofovir for pediatric recurrent respiratory papillomatosis.
TLDR
Comparing disease response among children with recurrent respiratory papillomatosis who underwent combined surgical debulking and intralesional cidofovir injections vs repeated surgicaldebulking only helps determine the true impact of cid ofovir on management of this disease. Expand
Successful use of intralesional and intravenous cidofovir in association with indole‐3‐carbinol in an 8‐year‐old girl with pulmonary papillomatosis
TLDR
This is the first report where a complete cure of the lung lesions occurred in a child, and was sustained for at least 24 months. Expand
...
1
2
3
4
...